This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is providing $415,902 to the University of Massachusetts Boston to conduct research on targeting the FOXA2/AP-1 axis to overcome lineage plasticity and therapy resistance in castration-resistant prostate cancer.
The key objectives of this 5-year project are to: 1) determine whether FOXA2 expression drives luminal prostate cancer cells into a multilineage transition state, 2) investigate how FOXA2 rewires AP-1 to drive lineage reprogramming, and 3) assess the therapeutic potential of inhibitors targeting the FOXA2-AP-1 axis in preclinical prostate cancer models. The research aims to provide mechanistic insights into FOXA2's role in driving prostate cancer lineage plasticity and test a combination approach to target the FOXA2-AP-1 axis, with the goal of translating this treatment strategy into clinical trials to improve outcomes for patients with AR-independent prostate cancer.
Generated 3/25/25, 4:09 AM